N

Nichi-Iko Pharmaceutical Co Ltd
TSE:4541

Watchlist Manager
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Watchlist
Price: 0.0001 JPY Market Closed
Market Cap: 776 550.9T JPY
Have any thoughts about
Nichi-Iko Pharmaceutical Co Ltd?
Write Note

Nichi-Iko Pharmaceutical Co Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nichi-Iko Pharmaceutical Co Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Total Liabilities
ÂĄ247.2B
CAGR 3-Years
9%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Total Liabilities
ÂĄ7.7T
CAGR 3-Years
2%
CAGR 5-Years
-1%
CAGR 10-Years
14%
Daiichi Sankyo Co Ltd
TSE:4568
Total Liabilities
ÂĄ1.7T
CAGR 3-Years
28%
CAGR 5-Years
17%
CAGR 10-Years
8%
Otsuka Holdings Co Ltd
TSE:4578
Total Liabilities
ÂĄ1.1T
CAGR 3-Years
9%
CAGR 5-Years
4%
CAGR 10-Years
8%
Chugai Pharmaceutical Co Ltd
TSE:4519
Total Liabilities
ÂĄ255.7B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
7%
Astellas Pharma Inc
TSE:4503
Total Liabilities
ÂĄ1.9T
CAGR 3-Years
32%
CAGR 5-Years
23%
CAGR 10-Years
16%
No Stocks Found

Nichi-Iko Pharmaceutical Co Ltd
Glance View

Market Cap
776 550.9T JPY
Industry
Pharmaceuticals

Nichi-Iko Pharmaceutical Co., Ltd., founded in Toyama, Japan, weaves its narrative around the essential fabric of healthcare by pioneering affordable and accessible medication. As a distinguished player in the generic pharmaceutical industry, Nichi-Iko specializes in the development, manufacture, and sale of a broad spectrum of generic drugs. Driven by the mission to enhance quality of life, the company meticulously focuses on producing high-quality, cost-effective alternatives to branded medications, thereby easing the financial burden on healthcare systems and patients alike. Its portfolio spans various therapeutic areas, strengthening its presence in both domestic and international markets. By investing strategically in R&D and leveraging advanced production techniques, Nichi-Iko ensures that its offerings meet rigorous standards, reinforcing trust and reliability in its brand. Financially, Nichi-Iko's revenue stream primarily hinges on the consistent demand for generics, amplified by the growing global emphasis on reducing healthcare costs. Licensing agreements and partnerships further bolster its financial framework, allowing the company to expand its product range and reach. The business model thrives on optimizing supply chain efficiencies and achieving economies of scale, translating into competitive pricing. Nichi-Iko’s commitment to innovation is not confined to generics; it is also venturing into biosimilars, tapping into a burgeoning market with expansive growth potential. By aligning its strategic direction with emerging healthcare trends and regulatory landscapes, Nichi-Iko positions itself as a resilient entity capable of sustaining its growth trajectory in a dynamic pharmaceutical sector.

Intrinsic Value
Not Available
N

See Also

What is Nichi-Iko Pharmaceutical Co Ltd's Total Liabilities?
Total Liabilities
247.2B JPY

Based on the financial report for Mar 31, 2022, Nichi-Iko Pharmaceutical Co Ltd's Total Liabilities amounts to 247.2B JPY.

What is Nichi-Iko Pharmaceutical Co Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
6%

Over the last year, the Total Liabilities growth was -2%. The average annual Total Liabilities growth rates for Nichi-Iko Pharmaceutical Co Ltd have been 9% over the past three years , 6% over the past five years .

Back to Top